Johnson & Johnson Innovation and Janssen Pharmaceutical Partner with Chia Tai Tianqing Pharmaceutical

Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. have announced an exclusive license agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a Chinese domestic pharmaceutical company and subsidiary of Sino Biopharma, Ltd. to develop, manufacture and commercialize, outside of China, undisclosed immune-modulating agents to treat human diseases, including curative treatment of chronic Hepatitis B virus infection.
According to the press release:

The agreement, facilitated by Johnson & Johnson Innovation, Janssen Business Development, follows the recent acquisition of Novira Therapeutics, Inc. and collaborations with Ichor Medical Systems, Inc. and the University of the Witwatersrand in South Africa, to address the significant unmet medical need inflicted by HBV. Chronic Hepatitis B is a potentially fatal liver disease with approximately 60 percent of hepatocellular carcinoma cases attributed to infection with the Hepatitis B virus. Current therapies are unable to cure the infection, requiring most people to endure lifelong treatment. More than 350 million people are infected with HBV worldwide.

Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson commented:

Johnson & Johnson Innovation’s mission is to identify the best science around the world to advance important therapies and products for patients and consumers.
Today, we are announcing an important new collaboration with Chia Tai Tianqing Pharmaceutical Group, which along with our additional new collaborations in the Hepatitis B area, demonstrates the strength and capabilities of our worldwide innovation model.

Click here to view the full press release.